On July 25, 2025, the Office of Patented Medicines and Liaison of Health Canada released its Statistical Report 2024/2025 for the Patented Medicines (Notice of Compliance) Regulations, Data Protection (C.08.004.1 of the Food and Drug Regulations), and Certificates of Supplementary Protection.
As with previous reports (see our article on the 2023/2024 Report), the report includes information regarding trends in the eligibility of patents for listing on the Patent Register, the eligibility of drugs for listing on the Register of Innovative Drugs, Certificates of Supplementary Protection, and related court activity for each topic.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance group.
The preceding is intended as a timely update on Canadian intellectual property and life sciences regulatory law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Consultation on proposed interim approach to reduce review timeline to 180 days for certain pediatric drugs
On September 14, 2026, Health Canada launched a consultation seeking public feedback on a proposed “new interim approach to speed up the review of certain pediatric drugs”, including on the proposed e...Read More -
Health Canada updates policies on foreign regulatory actions, summary reporting, compliance & enforcement and requests for new data
Health Canada announced a number of new and updated guidance documents and policies in September 2026, including the following.Read More -
Health Canada’s modernization of clinical trial framework: notice of interim policy and results from consultation
As we previously reported, Health Canada consulted on the framework for clinical trials, including on the new Clinical Trials Regulations and draft and updated guidance documents. Health Canada has no...Read More
